Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial
Open Access
- 11 October 2021
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 196 (4) , E33-E37
Abstract
No abstract availableKeywords
Funding Information
- Blood Cancer UK
- Janssen Pharmaceutica
This publication has 11 references indexed in Scilit:
- Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 StudyBlood, 2020
- Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte TrialBlood, 2020
- Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 TrialBlood, 2020
- Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple MyelomaJournal of Clinical Oncology, 2020
- Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 studyThe Lancet Haematology, 2020
- Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timingBlood, 2019
- Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myelomaBlood, 2018
- Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent InductionJAMA Oncology, 2018
- Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyondLeukemia, 2017
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for MyelomaNew England Journal of Medicine, 2017